Skip to main content

Table 4 Upper respiratory tract and other characteristics before initiation of anti-IL5/IL5R or anti-IgE treatment. The time of use describes mean time of use of biological therapy in months

From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences

Characteristics

Anti-IL5/IL5R

Anti-IgE

Reslizumab, Mepolizumab, Benralizumab, n = 38

Omalizumab, n = 17

Asthma (number, (%))

38 (100)

17 (100)

Nasal polyposis as only indication for biological therapy (number, (%))

3 (8)

0 (0)

Time of use (months) a

12.4 (1–29. SD 7.6)

43.8 (5–109. SD 35.6)

Age at analysis (years)

54.2 (25–72. SD 10.8)

47.6 (28–76. SD 11.5)

Women (number, (%))

18 (47)

12 (71)

BMIb (kg/m2)

28.1 (16.9–38.8. SD 4.8)

27.6 (23–35. SD 3.3)

Use of intranasal corticosteroids (number, (%))

34 (89)

14 (82)

Use of oral antihistamine (number, (%))

13 (34)

8 (47)

Use of montelukast (number, (%))

27 (71)

9 (53)

Positive skin prick test or allergen specific serum IgE (number, (%))

16 (42)

17 (100)

Smokers (number, (%))

1 (3)

0 (0)

Ex-smokersc (number, (%))

9 (24)

2 (12)

Nasal polyposis (number, (%))

29 (76)

11 (65)

Chronic rhinosinusitis (CRSwNP or CRSsNP) (number, (%))

34 (89)

15 (88)

ASA intolerance (number, (%))

9 (24)

3 (18)

Osteoporosis (number, (%))

12 (32)

4 (24)

Blood eosinophil count (E9/l)

0.48 (0.00–1.84. SD 0.38)

0.50 (0.01–1.21. SD 0.42)

  1. aTime of use of biological therapy
  2. bBMI = Body mass index
  3. cDefined as previous daily smoking at minimum 1 year